<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE Over half of newly diagnosed <z:mp ids='MP_0001261'>obese</z:mp> African Americans with <z:hpo ids='HP_0001953'>diabetic ketoacidosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DKA</z:e>) discontinue insulin therapy and go through a period of near-normoglycemia remission </plain></SENT>
<SENT sid="1" pm="."><plain>This subtype of <z:mp ids='MP_0002055'>diabetes</z:mp> is known as <z:hpo ids='HP_0001946'>ketosis</z:hpo>-prone type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (KPDM) </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS To investigate the role of lipotoxicity on beta-cell function, eight <z:mp ids='MP_0001261'>obese</z:mp> African Americans with KPDM, eight <z:mp ids='MP_0001261'>obese</z:mp> subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with severe <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> without <z:hpo ids='HP_0001946'>ketosis</z:hpo> (<z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>), and nine nondiabetic <z:mp ids='MP_0001261'>obese</z:mp> control subjects underwent intravenous infusion of 20% intralipid at 40 ml/h for 48 h </plain></SENT>
<SENT sid="3" pm="."><plain>beta-Cell function was assessed by changes in insulin and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> concentration during infusions and by changes in <z:hpo ids='HP_0011009'>acute</z:hpo> insulin response to arginine stimulation (AIR(arg)) before and after <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS The mean time to discontinue insulin therapy was 11.0 +/- 8.0 weeks in KPDM and 9.6 +/- 2.2 weeks in <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (P = NS) </plain></SENT>
<SENT sid="5" pm="."><plain>At remission, KPDM and <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> had similar <z:chebi fb="105" ids="17234">glucose</z:chebi> (94 +/- 14 vs. 109 +/- 20 mg/dl), A1C (5.7 +/- 0.4 vs. 6.3 +/- 1.1%), and baseline AIR(arg) response (34.8 +/- 30 vs. 64 +/- 69 microU/ml) </plain></SENT>
<SENT sid="6" pm="."><plain>P = NS despite a fourfold increase in free fatty acid (FFA) levels (0.4 +/- 0.3 to 1.8 +/- 1.1 mmol/l, P &lt; 0.01) during the 48-h intralipid infusion; the response to AIR(arg) stimulation, as well as changes in insulin and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels, were similar among <z:mp ids='MP_0001261'>obese</z:mp> patients with KPDM, patients with <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and nondiabetic control subjects </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS Near-normoglycemia remission in <z:mp ids='MP_0001261'>obese</z:mp> African American patients with KPDM and <z:hpo ids='HP_0001946'>ketosis</z:hpo>-resistant type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with a remarkable recovery in basal and stimulated insulin secretion </plain></SENT>
<SENT sid="8" pm="."><plain>A high FFA level by intralipid infusion for 48 h was not associated with beta-cell decompensation (lipotoxicity) in KPDM patients </plain></SENT>
</text></document>